-+ 0.00%
-+ 0.00%
-+ 0.00%

Adocia Preclinical Data Support Once-Monthly Dosing of Semaglutide Formulation

PUBT·11/16/2026 06:30:46
Listen to the news
Adocia Preclinical Data Support Once-Monthly Dosing of Semaglutide Formulation
  • Adocia presented preclinical results supporting potential once-monthly AdoXL Sema dosing at ObesityWeek 2026, held November 14-17 in Washington.
  • Animal studies showed longer circulation than semaglutide, with comparable effects on body weight.
  • Separate laboratory tests showed AdoXLong preserved retatrutide's activity across its three target receptors.
  • The platform remains preclinical; development plans prioritize clinical evaluation and pharmaceutical partnerships.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261115406471) on November 16, 2026, and is solely responsible for the information contained therein.